Get Adobe Flash player

The gene therapy company agreed in February on a merger with the Swiss pharmaceutical giant, but the conclusion has been postponed several times as competition authorities discuss the deal. « Once the merger is complete, Spark will become a wholly owned subsidiary of Roche, » Roche said. About Roche Roche is a global leader in drugs and diagnostics, which focuses on promoting science to improve people`s lives. The combined strengths of drugs and diagnostic medical devices under one roof have made Roche the market leader in personalized health care – a strategy that aims to provide every patient with the right treatment in the best possible way. Roche is the world`s largest biotechnology company with truly differentiated drugs in the fields of oncology, immunology, infectious diseases, ophthalmology and diseases of the central safety system. Roche is also the world leader in in vitro diagnosis and tissue diagnosis of cancer and a leader in diabetes management. Founded in 1896, Roche continues to look for better ways to prevent, diagnose and treat disease and make a lasting contribution to society. In addition, the company aims to improve patients` access to medical innovations by working with all relevant stakeholders. Thirty drugs developed by Roche are on the World Health Organization`s model lists of essential medicines, including life-saving antibiotics, antimalarials and anti-cancer drugs. Roche was also recognized for the tenth consecutive year by the Dow Jones Sustainability Indices (DJSI) as the most sustainable company in the pharmaceutical industry. Headquartered in Basel, Switzerland, the Roche Group operates in more than 100 countries and employed approximately 94,000 people worldwide in 2018. In 2018, Roche invested chf 11 billion in research and development and generated sales of CHF 56.8 billion.

Genentech in the United States is a 100% member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan. For more information, see www.roche.com. All trademarks used or mentioned in this press release are protected by law. IMPORTANT ADDITIONAL INFORMATION AND WHERE THERE IS THE TENDER OFFER FOR THE OUTSTANDING COMMON STOCK OF SPARK THERAPEUTICS HAS NOT STARTEDD. THIS AD IS ONLY FOR INFORMATION PURPOSES AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR SOLICITATION OF AN OFFER TO SELL SPARK THERAPEUTICS COMMON STOCK. THE SOLICITATION AND OFFER TO BUY SPARK THERAPEUTICS COMMON STOCK WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS. IN TIME THE OFFER IS COMMENCED, ROCHE AND ITS ACQUISITION SUBSIDIARY FILE A TENDER OFFER STATEMENT ON SCHEDULE TO WITH THE SEC AND THEREAFTER, SPARK THERAPEUTICS WILL FILE A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH RESPECT TO THE OFFER. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) CAREFULLY WHEN THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. OFFER ON PURCHASE, SOLICITATION/RECOMMENDATION STATEMENT AND RELATED MATERIALS WILL BE FILED WITH THE SEC, AND INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ROCHE AND SPARK THERAPEUTICS WITH THE SEC AT THE WEBSITE AT WWW.SEC.GOV. INVESTORS AND SECURITY HOLDERS MAY WWW.SPARKTX.COM ALSO PRES STATEMENT IN ZUKUNFT-LOOKING STATEMENTS SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING, AMONG OTHER THINGS, THE EXPECTED CONSUMMATION OF THE TRANSACTION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING THE SATISFACTION OF CLOSING CONDITIONS FOR THE TRANSACTION, THE TRANSACTION, INCLUDING REGULATORY APPROVAL, THE TENDER OF A MAJORITY OF THE OUTSTANDING SHARES OF COMMON STOCK OF SPARK THERAPEUTICS, THE POSSIBILITY THAT TRANSACTION NOT BE COMPLETED, AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN SPARK THERAPEUTICS` PUBLIC FILINGS WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE SEC`), INCLUDING THE RISK FACTORS SECTIONS OF SPARK THERAPEUTICS ` , SUCH AS ROCHE`S BID OFFER DOCUMENTS AND ITS ACQUISITION

Les commentaires sont fermés.